Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nippon Chemiphar Co., Ltd. currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners. This distribution shows that each examiner is responsible for exactly one of the pending office actions.
The company's pending matters are spread across 5 distinct art units. This variety suggests that the pending office actions involve several different technical specialties within Biotechnology & Pharmaceuticals. BRUCK KIFLE is the busiest examiner for this portfolio. This examiner is currently handling 1 pending office action.
Because BRUCK KIFLE and the other distinct examiners each handle a single pending office action, the workload is evenly distributed. The 5 distinct art units require the company to adapt to multiple administrative environments. The total 6 pending office actions represent the current workload for the company's patent prosecution efforts.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
| KASS, BENJAMIN JOSEPH | 1 | 32.6% | +58.9% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
| HAGHIGHATIAN, MINA | 1 | 46.1% | +39.3% |
| NEAGU, IRINA | 1 | 46.8% | +57.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17631635 | REAGENT CARTRIDGE | KASS, BENJAMIN JOSEPH | 105d overdue |
| 18694663 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | RAHMANI, NILOOFAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17631635 | REAGENT CARTRIDGE | KASS, BENJAMIN JOSEPH | 105d overdue |
| 18817846 | P2X4 RECEPTOR ANTAGONIST | KIFLE, BRUCK | — |
| 17615611 | THERAPEUTIC FOR GOUT OR HYPERURICEMIA | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 17057348 | METABOLISM IMPROVING AGENT | HAGHIGHATIAN, MINA | — |
| 16605885 | BLOOD PURIFICATION BY ALKALINIZING AGENT | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1691 | 1 |
| 1798 | 1 |
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18817846 | P2X4 RECEPTOR ANTAGONIST | KIFLE, BRUCK | — | DP | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18694663 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 17631635 | REAGENT CARTRIDGE | KASS, BENJAMIN JOSEPH | 1798 | §102§103§112Other | Final Rejection | 105d overdue | Pending | Jan 31, 2022 |
| 17615611 | THERAPEUTIC FOR GOUT OR HYPERURICEMIA | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §103Other | Non-Final OA | — | Pending | Dec 01, 2021 |
| 17057348 | METABOLISM IMPROVING AGENT | HAGHIGHATIAN, MINA | 1616 | §103 | Final Rejection | — | Pending | Nov 20, 2020 |
| 16605885 | BLOOD PURIFICATION BY ALKALINIZING AGENT | NEAGU, IRINA | 1629 | §103§112DP | Non-Final OA | — | Pending | Oct 17, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial